Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (61-70 of 194) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|November 21, 2002
Synthetic lethality: killing cancer with cancerKen Garber
Nature Biotechnology|February 1, 2003
Lymphoma market turf war imminent, pending Bexxar approvalKen Garber
Nature Biotechnology|April 12, 2017
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapyKen Garber
Nature Biotechnology|November 5, 2003
US NHGRI launches chemical attack on drug development gapKen Garber
Nature Biotechnology|April 3, 2004
Purchase of Aton spotlights HDAC inhibitorsKen Garber
Journal of the National Cancer Institute|April 3, 2003
Better blocker: RNA interference dazzles research communityKen Garber
Journal of the National Cancer Institute|December 5, 2003
Big plans for small molecules: NIH launches chemical genomics initiativeKen Garber
Journal of the National Cancer Institute|July 9, 2004
Running interference: pace picks up on synthetic lethality researchKen Garber
Nature Biotechnology|July 12, 2012
First FDA-approved beta-amyloid diagnostic hits the marketKen Garber
Journal of the National Cancer Institute|June 3, 2004
New gene discoveries may boost DNA stool testing for colorectal cancerKen Garber
Pageof 20

Showing results (61-70 of 194) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|November 21, 2002
Synthetic lethality: killing cancer with cancerKen Garber
Nature Biotechnology|February 1, 2003
Lymphoma market turf war imminent, pending Bexxar approvalKen Garber
Nature Biotechnology|April 12, 2017
Oncologists await historic first: a pan-tumor predictive marker, for immunotherapyKen Garber
Nature Biotechnology|November 5, 2003
US NHGRI launches chemical attack on drug development gapKen Garber
Nature Biotechnology|April 3, 2004
Purchase of Aton spotlights HDAC inhibitorsKen Garber
Journal of the National Cancer Institute|April 3, 2003
Better blocker: RNA interference dazzles research communityKen Garber
Journal of the National Cancer Institute|December 5, 2003
Big plans for small molecules: NIH launches chemical genomics initiativeKen Garber
Journal of the National Cancer Institute|July 9, 2004
Running interference: pace picks up on synthetic lethality researchKen Garber
Nature Biotechnology|July 12, 2012
First FDA-approved beta-amyloid diagnostic hits the marketKen Garber
Journal of the National Cancer Institute|June 3, 2004
New gene discoveries may boost DNA stool testing for colorectal cancerKen Garber
Pageof 20